RCS - Ondine Biomedical - UK Doctor Wins Award for NHS Steriwave Innovation

Ondine BiomedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250616:nRSP8533Ma&default-theme=true

RNS Number : 8533M  Ondine Biomedical Inc.  16 June 2025

16 June 2025

 

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

UK Doctor Wins Award for NHS Steriwave Innovation

Mid Yorkshire Teaching NHS Trust's Dr. Stuart Bond Honoured with President's
Award for Pioneering Use of Ondine's Steriwave Photodisinfection in the NHS

Ondine Biomedical Inc. (AIM: OBI) announces that Dr. Stuart Bond, Consultant
Antimicrobial Pharmacist and Director of Innovation at Mid Yorkshire Teaching
NHS Trust (Mid Yorks), has been awarded the President's Award at the 19th
World Congress of the International Photodynamic Association (IPA) in
Shanghai. This prestigious award is one of the IPA's highest honours, reserved
for individuals whose work is making a transformational impact on healthcare
through photodynamic therapy.

The IPA is a global organization dedicated to advancing research, education,
and clinical application of photodynamic technologies across medical and
biological fields. Dr. Bond was honoured for his pioneering leadership in
implementing antimicrobial photodynamic therapy (Ondine's Steriwave(®)
photodisinfection) in the UK's National Health Service (NHS), a groundbreaking
antimicrobial innovation used to prevent surgical site infections (SSI).

Dr. Bond and the teams at Mid Yorks were the first in the NHS to implement
pre-surgical photodisinfection using Ondine's Steriwave nasal therapy.
Deployed ahead of knee and hip replacement surgeries at Pinderfields and
Pontefract hospitals, the approach achieved a remarkable 71% reduction in SSI
over a six-month period. This achievement sets a new benchmark for infection
prevention and patient safety in the UK, while also delivering significant
cost savings to the NHS and greatly improving patient outcomes, all without
generating antimicrobial resistance.

Dr. Colin Hopper, President of the IPA said:

"Dr. Bond and his team at Mid Yorks were the first to operationalize
photodisinfection within the NHS. Their findings not only demonstrate the
clinical value of this approach but also underscore its importance in an era
of rising multi-drug resistance, positioning the UK's NHS as a global leader
in antibiotic stewardship and patient safety."

Carolyn Cross, CEO of Ondine Biomedical, commented:

"We are absolutely delighted to see Dr. Bond and his exceptional team
recognized for their visionary leadership, tireless efforts, and unwavering
commitment to improving patient care. Their remarkable achievements not only
highlight the Mid York's dedication to antibiotic stewardship but also
showcase their willingness to embrace innovative solutions in pursuit of
effective, resistance-free alternatives to antibiotics. This recognition by
the global photodynamic research and clinical community is truly well
deserved."

Ondine's Steriwave is a non-invasive and painless light-activated
antimicrobial therapy that destroys harmful pathogens in the nose, a major
source of infection, in minutes. The treatment involves applying a proprietary
photosensitive agent to each nostril followed by illumination with a specific
wavelength of red light. Steriwave is immediately effective against bacteria,
viruses, and fungi and does not contribute to antimicrobial resistance.
Already improving outcomes and reducing costs at leading hospitals, Steriwave
is gaining recognition as a powerful tool in the fight against
healthcare-associated infections and antibiotic resistance.

 

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABUGDLXBBDGUX